ArticleFrontiers in immunology2025

Phase I/II clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation: study rational and design.

Daniela Montagna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.